BTC $65,213.00 ▲ 1.64% ETH $1,929.79 ▲ 1.83% USDT $0.9994 ▲ 0.04% BNB $591.70 ▲ 0.07% XRP $1.04 ▼ 0.32% SOL $73.94 ▲ 1.41% DOGE $0.0700 ▲ 2.38% SHIB $0.00000465 ▼ 0.88% PEPE $0.00000284 ▲ 1.78% BTC $65,213.00 ▲ 1.64% ETH $1,929.79 ▲ 1.83% USDT $0.9994 ▲ 0.04% BNB $591.70 ▲ 0.07% XRP $1.04 ▼ 0.32% SOL $73.94 ▲ 1.41% DOGE $0.0700 ▲ 2.38% SHIB $0.00000465 ▼ 0.88% PEPE $0.00000284 ▲ 1.78%
İçerik Alanı728x90

Research 07.08.2026

Research 07.08.2026

🌏Markets:

🆕Economic News:
  • 08:30 USA – Non Farm Payrolls
  • 08:30 USA – Unemployment Rate
  • 08:30 USA – Average Hourly Earnings
📈 Gap Ups
Reaction to earnings/guidance:
Other news:
📉 Gap Downs
Reaction to earnings/guidance:
Other news:
  • INVX offering of 5,000,000 Shares
  • ESLT Announces the Results of its Annual General Meeting of Shareholders
  • SKHY Reveals $38B Expansion Plan Amid AI Hyperscaler Capex Frenzy
‼️Additional
  • Alphabet GOOGL holds 551.2 million Class A shares of SpaceX SPCX on its balance sheet — SEC filing.
  • The Senate is heading into recess, and the vote on the CLARITY Act has been postponed until September. BTC
  • The US Federal Aviation Administration ordered inspections of hundreds of BA Boeing 737 Max aircraft due to the risk of fuselage cracks.
  • AMD is acquiring Canadian startup Taalas to produce new types of AI chips for the rapidly growing data center industry.
🏢IPO
  • BLSM – BlossomHill Therapeutics
    Company develops small-molecule cancer drugs. Lead candidate BH-30643 is being tested for EGFR-mutant non-small cell lung cancer, a major lung cancer subtype where treatment can vary depending on the mutation. The company also has programs for AML / higher-risk MDS and a preclinical KRAS cancer program.
  • Price: $16.00
  • Shares: 9.4M
  • Raised: $150.0M
  • Market Cap: ~$490.3M
    LTM:
  • Revenue: $0
  • Net Income: -$71.1M
    Key point:
  • IPO was upsized from 7.81M to 9.38M shares, while the lead program remains early clinical with Phase 2 planning still ahead.
  • Comparable public companies: BMY , MRK , AZN , DAVA , NUVL , KURA
  • LTGO – Latigo Biotherapeutics
    Company develops non-opioid oral therapies for acute and chronic pain. Lead candidate LTG-001 is an oral Nav1.8 inhibitor for moderate to severe acute pain, including post-operative pain, with Phase 3 trials expected to start in H2 2026. Pipeline also includes LTG-321 for chronic musculoskeletal pain, starting with knee osteoarthritis, and earlier-stage Nav1.8 programs for other pain indications.
  • Price: $18.00
  • Shares: 19.2M
  • Raised: $345.6M
  • Market Cap: ~$1.15B
    LTM:
  • Revenue: $0
  • Net Income: -$111.2M
    Key point:
  • IPO was upsized from 16.0M to 19.2M shares and priced at the top of the range, while the company still has no approved products.
  • Comparable public companies: VRTX , SRPT , BMRN , HALO , EWTX , PRAX
  • MDAT – Web3Labs Global Inc.
    Company provides Web3 business services for blockchain companies and decentralized tech startups in Asia. Services include strategic consulting, acceleration program management, marketing, market research and operational support. The company also works with public blockchain ecosystems and aims to help Web3 startups commercialize decentralized products and establish a presence in Hong Kong.
  • Price: $4.00–$5.00
  • Shares: 6.3M
  • Raised: ~$28.1M
  • Market Cap: ~$140.0M
    LTM:
  • Revenue: $2.0M
  • Net Income: $0.88M
    Key point:
  • Business is profitable but very small, with only 17 employees and high exposure to Web3 / crypto market cycles.
  • Comparable public companies: BTCS , FRGT , GREE , MARA , RIOT , CLSK

📋 List of tickers involved:
$DOCX TEAM FIGS FROG TWLO NET ACMR CART NTRA AKAM INOD DV AAOI ABNB ONTO MCHP MP GMAB OKLO UA TTWO MNST PBR AFL WPM VATE AU GLD GDX HMY GFI HYMC GRML PLG SBSW USAR COHR GLW LITE AXTI FSLR RKLB MB NAMI TTD SEZL AMRZ VST CLMT PGNY LASR RMD DKNG RKT ROKU INVX ESLT SKHY GOOGL SPCX BTC BA AMD BLSM BMY MRK AZN DAVA NUVL KURA LTGO VRTX SRPT BMRN HALO EWTX PRAX MDAT BTCS FRGT GREE MARA RIOT CLSK

Best regards – hi2morrow team.

Yorumlar (0)

Yorum yapmak için giriş yapın.

Henüz yorum yapılmamış. İlk yorumu siz yapın.

İçerik Alanı728x90